Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 1 (1), 6-11
eCollection

A Brief History of the Treatment of Viral Hepatitis C

Affiliations
Review

A Brief History of the Treatment of Viral Hepatitis C

Doris B Strader et al. Clin Liver Dis (Hoboken).

Figures

Figure 1
Figure 1
SVR rates for patients with HCV infections (genotypes 1–3) according to the treatment regimens and durations.
Figure 2
Figure 2
Frequency of liver‐related complications after treatment with PEG and RBV for patients with SVR and patients without SVR.
Figure 3
Figure 3
SVR rates with PEGα‐2a or IFNα‐2b and RBV according to the genotype.27
Figure 4
Figure 4
SVR rates with PEGα‐2b and RBV therapy for 48 weeks according to the genotype and the viral concentration.26
Figure 5
Figure 5
SVR rates for recipients of PEGα‐2a and RBV (two different doses) for 24 or 48 weeks.28
Figure 6
Figure 6
Virological responses to IFN, PEG, and RBV in two US registration trials demonstrating that RBV reduces virological relapse.26, 27
Figure 7
Figure 7
Overall SVR rates and SVR rates based on RVR [i.e., undetectable HCV RNA at week 8 (week 4 of triple therapy)] for treatment‐naive patients with HCV genotype 1 infections. Abbreviation: RGT, response‐guided therapy.73
Figure 8
Figure 8
SVR rates for treatment‐naive patients with chronic HCV genotype 1 infections who received triple therapy (TVR, PEG, and RBV) for 24 or 48 weeks according to the achievement or nonachievement of extended rapid virological response (eRVR; i.e., undetectable HCV RNA at weeks 4 and 12).75
Figure 9
Figure 9
SVR and relapse rates according to the treatment regimen. The DAAs were BOC and TVR.
Figure 10
Figure 10
End‐of‐treatment and SVR rates for treatment‐naive patients with genotype 1 or genotype 2/3 HCV infections who received standard‐of‐care therapy (PEG) versus treatment‐naive patients with genotype 1 infections who were treated with DAAs (BOC and TVR).
Figure 11
Figure 11
SVR rates for treatment‐naive patients with chronic HCV genotype 1 infections who were treated with PIs according to the achievement of extended rapid virological response (eRVR) and racial and histological characteristics.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

LinkOut - more resources

Feedback